Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: A retrospective validation study
PLOS Medicine · 2025
DOI: 10.1371/journal.pmed.1004574 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift PLOS Medicine, 2025. Verfasst von Milou M F Schuurbiers und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Circulating Tumor DNA, Lung Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Pharmaceuticals, Roche Nederland, MSD.
Abstract (Originalsprache)
Background Despite treatment with curative intent, many patients with localized non-small cell lung cancer (NSCLC) develop recurrence. The current challenge is to identify high-risk patients to guide adjuvant treatment. Identification of residual disease by detection of circulating tumor DNA (ctDNA) may allow more accurate clinical decision-making, but its reliability in NSCLC is not established. We aimed to build on previous data to validate a tissue-informed personalized ctDNA assay, to predict recurrence in patients with early-stage disease. Methods and findings Tumor tissue and plasma was collected from patients with stage 0–III NSCLC enrolled to LEMA ( L ung cancer E arly M olecular A ssessment trial, NCT02894853). Serial plasma was collected before and after definitive treatment, with the latter including key timeframes of interest (1–3 days post-treatment, between 14 and 122 days after treatment end, and ≥14 days after treatment end). Somatic mutations identified by tumor exome sequencing were used to design patient-specific assays, to analyze ctDNA. Results were compared and combined with an independent dataset (LUCID; LU ng C ancer C I rculating Tumour D na study, NCT04153526). In LEMA, 130 patients (57% male; median age 66 years (range 44–82); 69% adenocarcinoma, 22% squamous cell carcinoma (SCC); 3%/49%/19%/29% with stage 0/I/II/III) were treated with curative intent. Tumor tissue originated from surgical resection or diagnostic biopsy in 118 and 12 patients respectively. LUCID included 88 patients (51% male; median age 72 years (range 44–88); 63% adenocarcinoma, 31% SCC; 49%/28%/23% with stage I/II/III). Before treatment, ctDNA was detected in 48% LEMA and 51% LUCID patients. Sensitivity, specificity, positive and negative predictive value of ctDNA detection post-treatment (≥1 positive sample ≥14 days after treatment end) to predict recurrence were 61%, 97%, 92% and 84% for LEMA and 64%, 96%, 90% and 83% for LUCID. In the combined cohort, ctDNA detection after treatment was associated with shorter recurrence-free survival (hazard ratio (HR) 11.4 (95% confidence interval (CI) [7.0,18.7]; p < 0.001)) and overall survival (HR 8.1 (95% CI [4.6,14.2]; p < 0.001)), accounting for guarantee-time bias. Of note, a key limitation of this work was the irregular sample collection schedules, during routine follow-up visits, of both studies. Conclusions ctDNA detection predicted recurrence in independent retrospective cohorts with notable reproducibility, including near-identical detection rates and predictive values, confirming its ability to differentiate patients at high- versus low risk of recurrence. Our results support the potential of tissue-informed ctDNA analysis as a decision-support tool for adjuvant therapy in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, Netherlands.
- NeoGenomics, Inc., Fort Myers, Florida, United States of America.
- Department of Surgery, The Netherlands Cancer Institute, Amsterdam, Netherlands.
- Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
- Royal Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom.
- Cancer Research UK Cambridge Centre, Cambridge, United Kingdom.
ORCID-Profile: Milou M F Schuurbiers, Christopher G Smith, Koen J Hartemink, Robert C Rintoul, Kim Monkhorst, Bas L R Mandos, Anna L Paterson, Michel M van den Heuvel
Förderung
- Pfizer Pharmaceuticals
- Roche Nederland
- MSD
- Novartis
- AstraZeneca
- University of Cambridge, Cancer Research UK
- European Research Council
- National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre
Zitieren
APA
Schuurbiers, M. M. F., Smith, C. G., Hartemink, K. J., Rintoul, R. C., Gale, D., Monkhorst, K., Mandos, B. L. R., Paterson, A. L., van den Broek, D., Rosenfeld, N., van den Heuvel, M. M., & LEMA Study Group and the LUCID Study Group (2025). Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: A retrospective validation study. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1004574
Vancouver
Schuurbiers MMF, Smith CG, Hartemink KJ, Rintoul RC, Gale D, Monkhorst K, et al. Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: A retrospective validation study. PLOS Medicine. 2025. doi:10.1371/journal.pmed.1004574
BibTeX
@article{Schuurbiers2025,
author = {Schuurbiers, Milou M F and Smith, Christopher G and Hartemink, Koen J and Rintoul, Robert C and Gale, Davina and Monkhorst, Kim and Mandos, Bas L R and Paterson, Anna L and van den Broek, Daan and Rosenfeld, Nitzan and van den Heuvel, Michel M and LEMA Study Group and the LUCID Study Group, LEMA Study Group and the LUCID Study Group},
title = {Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: A retrospective validation study},
journal = {PLOS Medicine},
year = {2025},
doi = {10.1371/journal.pmed.1004574}
}
EUVIMED